Pifithrin-α enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 3, 2006, Pages 1153-1161

  Wehbe, Hania ^a   Henson, Roger ^a   Lang, Molly ^a   Meng, Fanyin ^a   Patel, Tushar ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AROMATIC HYDROCARBON RECEPTOR; GEMCITABINE; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE P38; PIFITHRIN ALPHA; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; BILE DUCT CARCINOMA; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DEREGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SEQUENCE ANALYSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BILE DUCT NEOPLASMS; CELL COUNT; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DNA, NEOPLASM; DRUG SYNERGISM; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; IMMUNOBLOTTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TOLUENE;

EID: 33751173877     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.109835     Document Type: Article

References (32)

1. Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L, Pelosi G, Goldstraw P, Sozzi G, and Pastorino U (2004) Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer 108:91-96.
2. Chen S, Nguyen N, Tamura K, Karin M, and Tukey RH (2003) The role of the Ah receptor and p38 in benzo[a]pyrene-7,8-dihydrodiol and benzo[a]pyrene-7,8- dihydrodiol-9,10-epoxide-induced apoptosis. J Biol Chem 278:19526-19533.
3. Constantinou C and Clemens MJ (2005) Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53. Oncogene 24:4839-4850.
4. De BA and Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189-3199.
5. el-Mahdani N, Vaillant JC, Guiguet M, Prevot S, Bertrand V, Bernard C, Parc R, Bereziat G, and Hermelin B (1997) Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br J Cancer 75:528-536.
6. Gudkov AV and Komarova EA (2005) Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 331:726-736.
7. Hoagland MS, Hoagland EM, and Swanson HI (2005) The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. J Pharmacol Exp Ther 314:603-610.
8. Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, and Hensold JO (2002) p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene 21:5325-5334.
9. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmuller G, et al. (1993) p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298.
10. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr, and Berchuck A (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513-1519.
11. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, and Gudkov AV (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (Wash DC) 285:1733-1737.
12. Kubicka S, Trautwein C, Schrem H, Tillmann H, and Manns M (1995) Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J Hepatol 23:412-419.
13. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, and Sonenberg N (2004) eIF4E-from translation to transformation. Oncogene 23:3172-3179.
14. Marienfeld C, Yamagiwa Y, Ueno Y, Chiasson V, Brooks L, Meng F, and Patel T (2004) Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. Gastroenterology 127:1787-1797.
15. Minich WB, Balasta ML, Goss DJ, and Rhoads RE (1994) Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic translation initiation factor eIF-4E: increased cap affinity of the phosphorylated form. Proc Natl Acad Sci USA 91:7668-7672.
16. Mitsumoto Y, Nakajima T, Marutani M, Kashiwazaki H, Moriguchi M, Kimura H, Okanoue T, Kagawa K, and Tada M (2004) Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry. Hum Pathol 35:350-356.
17. Park J, Gores GJ, and Patel T (1999a) Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology 29:1037-1043.
18. Park J, Tadlock L, Gores GJ, and Patel T (1999b) Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30:1128-1133.
19. Patel T (2006) Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3:33-42.
20. Pyronnet S (2000) Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochem Pharmacol 60:1237-1243.
21. Rassidakis GZ, Thomaides A, Wang S, Jiang Y, Fourtouna A, Lai R, and Medeiros LJ (2005) p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia 19:1663-1669.
22. Raught B and Gingras AC (1999) eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 31:43-57.
23. Scheper GC and Proud CG (2002) Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 269:5350-5359.
24. Scheper GC, Van KB, Hu J, Luo Y, Goss DJ, and Proud CG (2002) Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA. J Biol Chem 277:3303-3309.
25. Tadlock L and Patel T (2001) Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 33:43-51.
26. Tilleray V, Constantinou C, and Clemens MJ (2006) Regulation of protein synthesis by inducible wild-type p53 in human lung carcinoma cells. FEBS Lett 580:1766-1770.
27. Walker NJ, Crockett PW, Nyska A, Brix AE, Jokinen MP, Sells DM, Hailey JR, Easterling M, Haseman JK, Yin M, et al. (2005) Dose-additive carcinogenicity of a defined mixture of "dioxin-like compounds". Environ Health Perspect 113:43-48.
28. Weiss C, Faust D, Durk H, Kolluri SK, Pelzer A, Schneider S, Dietrich C, Oesch F, and Gottlicher M (2005) TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38-MAPK-dependent pathway. Oncogene 24:4975-4983.
29. Xu GW, Mymryk JS, and Cairncross JG (2005) Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. Int J Cancer 116:187-192.
30. Yamagiwa Y, Marienfeld C, Tadlock L, and Patel T (2003) Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. Hepatology 38:158-166.
31. Yin B, Kogan SC, Dickins RA, Lowe SW, and Largaespada DA (2006) Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp Hematol 34:631-641.
32. Zhu X, Yu QS, Cutler RG, Culmsee CW, Holloway HW, Lahiri DK, Mattson MP, and Greig NH (2002) Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7- hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J Med Chem 45:5090-5097.